Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of Basmisanil in Participants Aged 2 to 14 Years Old With Dup15q Syndrome

NCT07846215 is registered in ClinicalTrials.gov with Newleos Therapeutics, Inc. as lead sponsor.

NCT NCT07846215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07846215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of Basmisanil in Participants Aged 2 to 14 Years Old With Dup15q Syndrome
Lead sponsor
Newleos Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
May 1, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dup15q syndrome